The window for biotech initial public offerings cracked open several times in 2007, letting out a cool burst of post-JPMorgan deals, a fresh breeze of spring offerings and a gust of fall pricings. (BioWorld Today)
The window for biotech initial public offerings cracked open several times in 2007, letting out a cool burst of post-JPMorgan deals, a fresh breeze of spring offerings and a gust of fall pricings. (BioWorld Today)
Curis Inc. licensed its bone morphogenetic protein-7 (BMP-7) program to Stryker Corp., ending a seven-month search to replace former partner Ortho Biotech Products L.P. (BioWorld Today)
Curis Inc. licensed its bone morphogenetic protein-7 (BMP-7) program to Stryker Corp., ending a seven-month search to replace former partner Ortho Biotech Products L.P. (BioWorld Today)
VaxGen Inc. moved one step closer to realizing its proposed merger with Raven Biotechnologies Inc. as shareholders at yesterday's annual meeting re-elected VaxGen's current board of directors and approved a merger-related reverse stock split. (BioWorld Today)
VaxGen Inc. moved one step closer to realizing its proposed merger with Raven Biotechnologies Inc. as shareholders at yesterday's annual meeting re-elected VaxGen's current board of directors and approved a merger-related reverse stock split. (BioWorld Today)
Genitope Corp. revealed that cancer vaccine MyVax missed its primary endpoint in a pivotal Phase III trial, failing to improve progression-free survival compared to control in patients with follicular B-cell non-Hodgkin's lymphoma (NHL). (BioWorld Today)
